Title
Humoral immunity induced by mucosal and/or systemic SIV-specific vaccine platforms suggests novel combinatorial approaches for enhancing responses
Date Issued
01 January 2014
Access level
open access
Resource Type
journal article
Author(s)
Vargas-Inchaustegui D.
Mohanram V.
Musich T.
Pegu P.
Valentin A.
Sui Y.
Rosati M.
Bear J.
Venzon D.
Kulkarni V.
Alicea C.
Pilkington G.
Liyanage N.
Demberg T.
Gordon S.
Wang Y.
Hogg A.
Frey B.
Patterson L.
DiPasquale J.
Montefiori D.
Sardesai N.
Reed S.
Berzofsky J.
Franchini G.
Felber B.
Pavlakis G.
Robert-Guroff M.
Vaccine Branch
Publisher(s)
Academic Press Inc.
Abstract
Combinatorial HIV/SIV vaccine approaches targeting multiple arms of the immune system might improve protective efficacy. We compared SIV-specific humoral immunity induced in rhesus macaques by five vaccine regimens. Systemic regimens included ALVAC-SIV. env priming and Env boosting (ALVAC/Env); DNA immunization; and DNA plus Env co-immunization (DNA&Env). RepAd/Env combined mucosal replication-competent Ad- env priming with systemic Env boosting. A Peptide/Env regimen, given solely intrarectally, included HIV/SIV peptides followed by MVA- env and Env boosts. Serum antibodies mediating neutralizing, phagocytic and ADCC activities were induced by ALVAC/Env, RepAd/Env and DNA&Env vaccines. Memory B cells and plasma cells were maintained in the bone marrow. RepAd/Env vaccination induced early SIV-specific IgA in rectal secretions before Env boosting, although mucosal IgA and IgG responses were readily detected at necropsy in ALVAC/Env, RepAd/Env, DNA&Env and DNA vaccinated animals. Our results suggest that combined RepAd priming with ALVAC/Env or DNA&Env regimen boosting might induce potent, functional, long-lasting systemic and mucosal SIV-specific antibodies. © 2013.
Start page
308
End page
322
Volume
153
Issue
2
Language
English
OCDE Knowledge area
Inmunología Enfermedades infecciosas Virología Farmacología, Farmacia
Scopus EID
2-s2.0-84902682927
PubMed ID
Source
Clinical Immunology
ISSN of the container
15216616
Sponsor(s)
This work was supported in part by the Intramural Research Program of the National Cancer Institute , National Institutes of Health (NCI/NIH) (B.K.F., G.N.P., J.A.B., G.F., M.R.G.), and National Institute of Allergy and Infectious Diseases — NIH contract HHSN27201100016C (D.C.M.). G.N.P. and B.K.F. are inventors on US Government-owned patents and patent applications related to DNA vaccines and gene expression optimization. G.F. is an inventor on a US Government patent filed jointly with Sanofi Pasteur on the use of the ALVAC vector as a platform for an HIV vaccine. N.Y.S. is a full time employee of Inovio Pharmaceuticals and as such receives compensation in the form of salary and stock options. S.G.R. is a full time employee of Infectious Diseases Research Institute and as such receives compensation in the form of salary and stock options. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Sources of information: Directorio de Producción Científica Scopus